Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

Lancet. 2002 Mar 23;359(9311):1011-8. doi: 10.1016/s0140-6736(02)08091-1.


Background: Trials on the effect of systemic chemotherapy on survival and recurrence in adults with high-grade glioma have had inconclusive results. We undertook a systematic review and meta-analysis to assess the effects of such treatment on survival and recurrence.

Methods: We did a systematic review and meta-analysis using updated data on individual patients from all available randomised trials that compared radiotherapy alone with radiotherapy plus chemotherapy. Data for 3004 patients from 12 randomised controlled trials were included (11 published and one unpublished).

Findings: Overall, the results showed significant prolongation of survival associated with chemotherapy, with a hazard ratio of 0.85 (95% CI 0.78-0.91, p<0.0001) or a 15% relative decrease in the risk of death. This effect is equivalent to an absolute increase in 1-year survival of 6% (95% CI 3-9) from 40% to 46% and a 2-month increase in median survival time (1-3). There was no evidence that the effect of chemotherapy differed in any group of patients defined by age, sex, histology, performance status, or extent of resection.

Interpretation: This small but clear improvement in survival from chemotherapy encourages further study of drug treatment of these tumours.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Combined Modality Therapy
  • Female
  • Glioma / drug therapy*
  • Glioma / mortality
  • Glioma / radiotherapy
  • Humans
  • Male
  • Middle Aged
  • Nervous System Neoplasms / drug therapy*
  • Nervous System Neoplasms / mortality
  • Nervous System Neoplasms / radiotherapy
  • Randomized Controlled Trials as Topic
  • Survival Rate